All Psiconáutica articles arranged alphabetically. A directory to navigate the complete archive since 1996.
#
- “Albert Hofmann: Chance, Fate, and the Origin of LSD”
- “Alexander Shulgin: The Chemist Who Mapped the Mind”
- “Cannabis and Chemotherapy Nausea: Evidence, Risks, and Alternatives”
- “Cannabis and PTSD: Between Self-Medication and Clinical Evidence”
- “Cannabis: Avoiding Distress or Learning to Face It?”
- “Cocaine: Pharmacology, Risks, and Myths of a Stimulant”
- “DMT: The Tryptamine Within Us”
- “Entheogen or Hallucinogen: Bouso and the Shaman Myth”
- “Hemp as Biomass: Future Energy or Old Green Myth?”
- “Heroin in Spanish Music: Between Warning, Mockery, and Transgression”
- “Hofmann at 100: His Farewell and the Chemistry of Psilocybin”
- “Ibogaine and Addiction: Promises, Clinical Evidence, and Limitations”
- “Mystery Cults of Rome: Attis, Isis, and Mithras”
- “Oral vs. Inhaled Cannabis: Key Insights for Cancer Patients”
- “Peter Tosh: A Guitar as a Rifle Against Babylon”
- “Psychedelics and Personal Transformation: Between the Threshold and the Community”
- “Selegiline: History and Promises of the MAO-B Inhibitor”
- “The Celtic Pharmacopeia: Mushrooms, Nightshades, and Hemp”
- “The Restless Child Business: ADHD, Labels, and Pills”
- “Where Cannabis Comes From: The Equatorial African Trail”
- ‘How LSD Originated: Hofmann and the Years Before the Discovery’
- ‘LSD: My Problem Child – Albert Hofmann’s Preface’
- ‘Opium as a “Smart Drug”: History and Critical Analysis’
- ‘Peyote, San Pedro, and Mescaline: Mind-Altering Cacti’
- 1D-LSD and 1T-LSD: a distinction requiring chemical analysis
- 2C-B in PiHKAL: Re-reading Ann Shulgin’s Account Today
- 2C-B versus MDMA and psilocybin: acute effects in 24 people
- 5-MeO-DMT and alcohol: ten interviews within an open-label trial
- 5-MeO-DMT and postpartum depression: an open ten-woman pilot
- 5-MeO-DMT and the Sonoran toad: a historical critique of ancestrality
- 5-MeO-DMT and Treatment-Resistant Depression: Early Trial Results
A
- A 1967 LSD manual: user agreement in a survey
- A Guide to Using Salvia Divinorum
- A peripheral 5-HT2A agonist against tumors: preclinical research
- Absinthe: Between the Green Fairy Myth and Chemical Reality
- Absinthe: The Green Fairy Myth and the Science of Thujone
- Add-on ketamine in severe non-resistant depression: 40-patient pilot
- Addiction, Spirituality, and Western Science
- Addiction, Spirituality, and Western Science
- Adolescent 25C-NBOMe and social competition: a male-rat study
- Adrenochrome (VIII): A Sublingual Trip Report
- Adrenochrome: A Bioassay Chronicle and the Role of Vitamin B3
- Adrenochrome: Anatomy of a Hoax Between QAnon and the Pandemic
- Adrenochrome: Anatomy of a Myth Between Fiction and Delusion
- Adrenochrome: Between the Laboratory and Online Forums
- Adrenochrome: From Conspiracy Myth to Real Science
- Adrenochrome: Hidalgo’s Conclusion and Lingering Scientific Questions
- Adrenochrome: Osmond and Hoffer’s Self-Experiments
- Adrenochrome: The Final Tasting, a Shot, and Plenty of Myth
- Adrenochrome: The Psychedelic Myth vs. Real-World Experiences
- Albert Hofmann and Ergot: The Origins of LSD
- Albert Hofmann and LSD: History of a Problem Child
- Albert Hofmann and LSD: Life and Legacy of the Swiss Chemist
- Albert Hofmann and the Magic Drugs: Psilocybin and Ololiuqui
- Albert Hofmann Beyond LSD: Chemistry, Consciousness, and Mystery
- Albert Hofmann Interviewed by Josep Mª Fericgla
- Albert Hofmann: The Chemist Who Sought a Medicine for the Soul
- Alcohol Extractions
- Alexander Shulgin: The Chemist Who Mapped the Mind
- Alzheimer’s Disease and Cannabidiol: Scientific Perspectives and Precautions
- Amanita muscaria: History and Reality of the First Entheogen
- Amanita, Psilocybe, and San Pedro: The Psychoactive Iberian Peninsula
- Amphetamines: History, Pharmacology, and Risks of a Stimulant
- Amsterdam’s Cannabis Museum: A History of the Plant
- An experimental plant produces five psychedelic tryptamines
- Ann Shulgin and the “Cold Mind”: When the Trip Doesn’t End
- Ann Shulgin on MDMA-Assisted Psychotherapy
- Ann Shulgin: MDMA Therapy and the Shadow
- Ann Shulgin’s “Secret Place” and the Enigma of 2C-D
- Antonio Escohotado on Drugs: Use, Abuse, and Prohibition
- Antonio Escohotado, Part II: From Amnesia to His History of Drugs
- Antonio Escohotado’s Magnum Opus, Translations, and Music
- Anxiety, Interferon, and Cannabinoids: A Clinical Perspective
- Arcanum Arcanorum: The Secret of the Secrets
- Arcanum Arcanorum: The Secret of the Secrets
- ASCENT-IBO: a clinical research call for ibogaine
- Aspirin or White Willow? The Truth About Common Painkillers
- Australia: supervision of MDMA and psilocybin under authorized prescribing
- Australia: supervision requirements for MDMA and psilocybin
- Australian MDMA-related deaths: trends and polydrug toxicity
- Ayahuasca and Depression: What the Randomized Placebo Trial Showed
- Ayahuasca and DMT: 26 trial registrations through July 2025
- Ayahuasca and emotional symptoms in cancer: a six-woman pilot
- Ayahuasca and Fear Memory in Rats: Less Freezing and More Dendritic Spines
- Ayahuasca and mental health: an association in a Brazilian survey
- Ayahuasca and social connectivity: a twelve-person fMRI study
- Ayahuasca in Mas d’en Carles: A Skeptic’s Chronicle
- Ayahuasca Visions: What the Brain Reveals (Part II)
- Ayahuasca: a review of botanical diversity and evidence gaps
- Ayahuasca: Science, Tradition, and Harm Reduction
B
- Barrow announces funding to study ibogaine in traumatic brain injury
- Base Cocaine and Crack: What They Are and How They Differ
- Bena-Riamba: The Sons of Hemp in 19th-Century Congo
- Beyond THC and CBD: Minor Cannabinoids and Terpenes
- Beyond THC and CBD: The Therapeutic Potential of Minor Cannabinoids
- Beyond THC and CBD: The Vast World of Other Cannabinoids
- Bicycle Day: Albert Hofmann and the First LSD Trip
- Biological Contaminants in Cannabis: Real Risks and Myths
- Blinding in psychedelic trials: only 33 of 112 assessed it
- Blue Lotus: Egyptian Myth, Alkaloids, and Psychoactive Legend
- BOL-148: Ceruvia announces funding for cluster headache research
- Brazil: federal prosecutors recommend reviewing ayahuasca rules
- Buprenorphine after ketamine: a four-week suicidal-ideation signal
- Buprenorphine: History, Pharmacology, and Role in Addiction Treatment
- Burundanga: Between Media Myth and Toxicological Reality
C
- Canada: controlled-substance rules and access to psilocybin
- Cannabidiol (CBD) and Childhood Epilepsy: Hope and Clinical Caution
- Cannabidiol (CBD): Neuroprotection, Mental Health, and Antipsychotics
- Cannabidiol and Addictive Disorders: Evidence, Myths, and Cautions
- Cannabidiol for Myoclonus: Evidence, Risks, and Stress Management
- Cannabidiol: Between Therapeutic Hope and Scientific Reality
- Cannabinoid Hyperemesis Syndrome: Between Relief and Clinical Rarity
- Cannabinoids and Glioblastoma: Science, Hope, and Reality
- Cannabinoids for Neuropathic Pain: An Evidence-Based Tool
- Cannabis According to Escohotado: Rereading a Classic
- Cannabis Addiction: Is It in the Plant or the Person?
- Cannabis Adulterants: What Forensic Lab Analyses Actually Reveal
- Cannabis Adulterants: What Laboratory Tests Reveal
- Cannabis and Academic Performance: Myths, Data, and Neuroscience
- Cannabis and ADHD: Science, Legal Risks, and the Natural Myth
- Cannabis and Anorexia Nervosa: A Real Solution or a Risk?
- Cannabis and Chemotherapy: Symptom Management in Oncology
- Cannabis and Creativity: Concepts, Dopamine, and Open Minds
- Cannabis and Crohn’s Disease: Clinical Evidence and Risk Reduction
- Cannabis and Driving: Risks, Tolerance, and Legal Complexities
- Cannabis and Emotional Distress: When It Becomes the Only Way Out
- Cannabis and Emotions: Learning to Read Your Own Responses
- Cannabis and Fertility: Between Medical Myth and Scientific Evidence
- Cannabis and Fibromyalgia: Medical Controversy and Symptom Relief
- Cannabis and HIV: Balancing Symptom Relief and Metabolic Health
- Cannabis and HIV: Scientific Evidence for Chronic Symptom Management
- Cannabis and Inflammatory Bowel Disease: Evidence, Risks, and Outlook
- Cannabis and Lung Health: Chronic Bronchitis and Risk Reduction
- Cannabis and Meditation: Examining the Content-Free Mind
- Cannabis and Meditation: Focus, Mind, and Caution
- Cannabis and Meditation: Seeking Equanimity
- Cannabis and Memory: Between Scientific Myth and Clinical Reality
- Cannabis and Memory: The Culprit or a Factor in Chronic Pain?
- Cannabis and Migraine: Evidence, Myths, and Harm Reduction
- Cannabis and Multiple System Atrophy: A Critical Look
- Cannabis and Neurodegenerative Diseases: Alzheimer’s and Parkinson’s
- Cannabis and Neurodegenerative Diseases: MS, Alzheimer’s, and Parkinson’s
- Cannabis and Neuropathic Pain: Scientific Evidence for Management
- Cannabis and Parkinson’s Disease: Scientific Evidence and Risk Reduction
- Cannabis and Pregnancy: Scientific Evidence, Risks, and Patient Rights
- Cannabis and Psychosis: What the Evidence Says
- Cannabis and Rare Neurodegenerative Diseases: Evidence and Risk
- Cannabis and Rheumatoid Arthritis: Science and Risk Reduction
- Cannabis and Self-Awareness: How It Alters the Sense of Self
- Cannabis and Self-Regulation: Coping or Escaping?
- Cannabis and Spain’s Left-Wing Parties: A Fragile Alliance
- Cannabis and the Big Five: Does It Modulate Personality?
- Cannabis as an Adjuvant for Cauda Equina Syndrome: Evidence and Risks
- Cannabis Desserts: Traditional Infused Recipes
- Cannabis Edibles: Why Dose Changes Everything
- Cannabis Oil Extraction: A Step-by-Step Guide
- Cannabis Pasta Recipe: How to Make Sugo Sconvolto
- Cannabis Shrimp Pâté Recipe
- Cannabis Soup: The Mariano Broth Recipe
- Cannabis Vaporization: Scientific Advances and Harm Reduction
- Cannabis, Anxiety, and Self-Regulation: Mental Space or Escapism?
- Cannabis, Emotions, and Daily Conflicts (Part II)
- Cannabis, Health, and Driving: Pain Relief vs. Roadside Testing
- Cannabis, Lung Cancer, and Science: Moving Beyond the Fear
- Cannabis, Type 2 Diabetes, and the Endocannabinoid System
- Cannabis-Infused Crazy Pork: A Culinary Guide
- Carbonara Chawen: A Cannabis-Infused Pasta Recipe
- CBD and Pediatric Epilepsy: Between Clinical Hope and Scientific Caution
- Cebil and Yopo: The Seeds of Bufotenine
- Celtas Cortos: Celtic Music, Rock, and Cannabis Culture
- Cheese and Dreams: Stilton Legends and the Science of Sleep
- CHEMSAFE Catalunya: harm reduction and support announced by ABD
- Chemsex: Between Clinical Reality and Media Narrative
- Chemsex: Between Scientific Data and Media Sensationalism
- Clinical and non-clinical ketamine: perceived effectiveness in a survey
- Clinical psilocybin in Zurich: a 19-person retrospective cohort
- Coca and Cocaine: A History of Power, Ritual, and Chemistry
- Coca Leaf and Ephedra: A European Legal Paradox
- Cocaine in 27% of reported deaths across 20 European countries
- Cocaine Purity and Adulteration: The Reality of the Illicit Market
- Cocaine Purity and Duration: Facts, Myths, and Harm Reduction
- Cognimiscence
- Cognition and Psychology of the Shuar (Jivaro) People
- Cold Soups and Edible Cannabis: A Critical Look
- Colorado and ibogaine: law, conditional funding and permits to verify
- Colorado creates a conditional framework for ibogaine research
- Colorado law establishes an ibogaine research pilot programme
- COMP360: Compass reports 26-week follow-up data
- Compass reports six-month COMP360 data for treatment-resistant depression
- Compassionate psilocybin in Germany: access and coverage in an interview
- Consensual Forced Intoxication: Ethics, Risks, and BDSM Dynamics
- Crack and Freebase Cocaine (Part II): Risks and Harm Reduction
- Cultivating Psilocybe cubensis: Biology, Culture, and Risks
- Cyanazenes: cellular potency and BTNX 2.0 strip detection
- Cyanazenes: receptor activity and detection in a laboratory assay
- CYB004: deuterated DMT in an exploratory phase 1 trial
- Czechia and psilocybin: what NUDZ clarified about access in March
D
- Dalí: Exploring Alternate States Without Substances
- DEA and 7-OH: what July’s threshold notice proposed
- DEA proposes Schedule I for five tryptamines: scope and evidence
- Def Con Dos: Rap Metal, Digital Control, and Critical Smoke
- Definium reports Voyage DT 120 results for generalized anxiety disorder
- Delaware: harm-reduction law and phased implementation
- Delix and J&J: reported $85 million round pending closure
- Designer benzodiazepines: searches and PRO Test sample reports
- DESOXY: The Shulgin Account of Emotional Blunting
- DESOXY: The Shulgin Account on Emotional Flattening
- Did Prehistoric European Populations Use Drugs? (Part I)
- DIMS PMMA warning: two-color pills bearing a Trump image
- DMT and 5-MeO-DMT: 51-Study Review Finds Early Signals in Depression
- DMT and addiction: observational signals from differing interventions
- DMT and depression: a two-week signal in a 34-person trial
- DMT and Depression: Insights from Early Clinical Trials
- DMT and harmine: EEG microstate changes in 25 volunteers
- DMT and human neural cells: proliferation in culture
- DMT and human neural stem cells: proliferation in culture
- DMT and Parkinson disease: preclinical findings, not human benefit
- DMT and Psychedelics: The Science That Prohibition Silenced
- DMT in mice: separating behavioral responses is not proof of therapy
- DMT versus 5-MeO-DMT: preliminary differences in mouse assays
- Does Cannabis Really Cause Amotivational Syndrome? A Critical Look at the Evidence
- Dosing Edible Cannabis: A Practical Guide
- Drug Prohibition: Escohotado’s Critique
- Drug scheduling: GAO identifies gaps at DEA and FDA
- Drugs and Literature: Creation in Altered States
- Drugs and Mental Health: Between Scientific Evidence and Myths of Fear
- Dutch Coffee Shops: The Back Door Dilemma
- Duto and Kisha: Heroin and Cocaine in 20th-Century Madrid
E
- E-cigarettes and Cannabis: Controversies, Harm Reduction, and Science
- Ecstasy and Health: A Rigorous Analysis of Physical and Psychiatric Risks
- Ecstasy and the Brain: Neurotoxicity Myths vs. Clinical Reality
- Ecstasy Cut with Heroin: Anatomy of an Urban Legend
- Ecstasy Purity and Adulteration: Spanish Market Data (1985–1995)
- Eleusis and the Kykeon: Hofmann’s Ergot Hypothesis
- Emerge: Definium reports DT120 results in depression
- Energy Control alert: PMMA and MDMA in two pills
- Energy Control: ten years of samples and adulteration limits
- Entheogenic Knowledge: The Path to Self-Discovery
- Entheogens, Shamans, and Psychonauts: A Journey of Consciousness
- Ergot: From Medieval Poison to Hofmann’s LSD
- Ergot: From St. Anthony’s Fire to Witchcraft
- Ergot: Poison, Entheogen, and Medicine
- Ernst Jünger and the Invention of the Word “Psychonaut”
- Ernst von Bibra and the First Treatises on Psychoactive Substances
- Ernst von Bibra, the Baron Who Cataloged the World’s Drugs
- Escohotado (I): The Philosopher, LSD, and Freak Ibiza
- Escohotado and Jack Herer: The Emperor Wears No Clothes
- Escohotado on Cannabis: Use, Abuse, and Prohibition
- Escohotado on Ecstasy and the Trap of Prohibition
- Escohotado: TV Fame, Trials, and Pharmacological Reason
- Escohotado’s Letter to the Mother of a Drug Addict
- Esketamine (Spravato): The Approved Antidepressant and How It Works
- Esketamine Alone in Treatment-Resistant Depression: What the 2025 Trial Shows
- Esketamine and dexmedetomidine after gynecological surgery
- Esketamine and recorded suicidal behavior: an uncertain result
- Esketamine in three Spanish centres: findings from a retrospective cohort
- ETH-LAD: a laboratory-confirmed poisoning case report
- Ethylbromazolam: UK accepts a recommendation for control
- EUDA 2026: harm-reduction availability and coverage gaps
- Expiration of Psychoactive Substances: Chemical Stability and Storage
F
- FDA and psychedelics: what the public hearing notice proposed
- FDA botanical-drug consultation: scope and regulatory limits
- FDA psychedelic guidance: trials, blinding and limitations
- FDA psychedelic hearing: scope of the July notice
- FDA psychedelic hearing: stakeholder views and regulatory scope
- FDA psychedelic-trial guidance: recommendations and limits
- Fentanyl: Lethal Potency, Medical Paradox, and Harm Reduction
- Fentanyl: NIST tracks adulterants in 17 U.S. states
- Fifty Years of Decoding Cannabis: From Mechoulam to the Endocannabinoid System
- Fisher applies to import DMT and other compounds for trials
- French ketamine guide: monitoring repeated or prolonged use
- From Coffee to Ritalin: Stimulants, Childhood, and the ADHD Myth
- From Entheogens to Psychedelics: A Short History
- From Entheogens to Psychedelics: The Stoned Ape Theory
- From the Canaries to Sonora: The Uncertain Route of Canary Broom
- Fuerteventura and Psychedelic Therapy: From Enthusiasm to Caution
G
- Gabon announces a draft ban on iboga and derivative exports
- Gecko Turner: Afromeño Soul, Remixes, and Creativity
- Getting High on Batteries: Anatomy of an Urban Legend
- Girona Ayahuasca Forum: an announced Indigenous-led agenda
- Glasgow Postpones Scotland’s First Drug Checking Service With No New Date
- Glasgow: drug-checking announcement and opening delay
- Groove 3: Bassless Jazz and the Groove as Shared Trance
- Guerrilla Growing: Preparation and Land Selection
- Guide to Entheogenic and Psychoactive Plants
H
- Hallucinogens and Mystical Experience: What Science Says
- Harm Reduction: Between Scientific Evidence and Political Rhetoric
- Hash with two synthetic cannabinoids: a Zurich sample
- Hashish According to Escohotado: Craft, Effects, and Risks
- Hashish Adulterants: What Do Laboratory Tests Actually Reveal?
- Hemp as Food: Real Nutrition and Myths About Hemp Seeds
- Hemp: The Fiber That Made Paper Possible
- Hepatitis C and Cannabis: Balancing Liver Risk and Treatment
- Heroin and Heartbreak: Eduardo Hidalgo’s Stigma-Free Memoir
- Heroin and Music: A Historical and Pharmacological Analysis
- Heroin and Music: Between Rock Myth and Clinical Reality
- Heroin in the 21st Century: Stigma and Scientific Evidence
- Heroin-Assisted Treatment: Scientific Evidence and Harm Reduction
- Hofmann and Huxley: LSD Between Serendipity and Vision
- Hofmann and LSD: Chemistry, Potency, and Toxicity
- Hofmann and Psilocybin: From Teonanácatl to the Test Tube
- Hofmann and Psychotomimetics: A Map of Magic Drugs
- Hofmann and the Entheogens of Mexico: From LSD to Psilocybin
- Hofmann, Huxley, and Jünger: Literature and Psychedelia
- Hofmann, Huxley, and Jünger: The Session That Named the Psychonaut
- Hofmann, Ololiuqui, and the Chemistry of Psychedelics
- How Anxiety Works: The Fear That Anticipates
- How Psilocybin Changes the Brain: Recent Evidence
- How to Differentiate Between LSD and 25i-NBOMe
- How to Dry, Cure, and Store Cannabis for Peak Quality
- How to Make Cannabis Oil Safely: A Practical Guide for Therapeutic Use
- HRSA seeks input on training and models for potential psychedelic therapies
- Huachuma tourism: reflections on tradition and benefit sharing
I
- Iboga and Voacanga: The African Vision and the Myth of the Cure
- Iboga in Gabon: sovereignty and traditional knowledge in Georges Gassita’s account
- IBOGAINE Act: what the June federal bill proposed
- Ibogaine and Addiction: The Evidence Medicine Ignores
- Ibogaine and arrhythmia: a pharmacovigilance preprint signal
- Ibogaine and ketamine dependence: one case followed for 17 months
- Ibogaine and Opioids: What Science Knows About Dependency
- Ibogaine and PTSD in veterans: one-year observational follow-up
- Ibogaine Cardiac Risks: QT Prolongation and Safety
- Ibogaine for Traumatic Brain Injury: What Stanford Found
- Ibogaine Legality and Clinics Worldwide: What We Know
- Ibogaine: FDA consultation on trials and safety
- Ibogaine: federal research support and unresolved cardiac risk
- If Skiing Were Illegal: A Satire on Prohibitionism
- Imagination and Cannabis: What Really Changes?
- Indole Chemistry: Understanding Entheogens
- Inhaled DMT and wellbeing: two open-label follow-up studies
- Interview With Juanjo Piñeiro
- Interviewing Josep Mª Fericgla: A Pioneer in Entheogen Studies
- Iowaska in Iowa: state registration, federal permits unverified
- Ireland Publishes 2026-2030 National Drugs Strategy Without Decriminalizing Possession
- Ireland: committee proposes decriminalizing possession for personal use
- Ireland: historical warning on cathinones sold as MDMA
- Is Cannabis Addictive? Distinguishing Myth from Scientific Evidence
- Is Getting High Natural? What the Animal Kingdom Teaches Us
- Isaacs-Mertens Syndrome and Cannabis: Clinical Evidence and Harm Reduction
- IV ketamine and esketamine: a records association reported by NRx
- IV ketamine and esketamine: no significant difference in a small cohort
J
- Jenkem: The Myth of the Fecal Drug Debunked
- Juan José García Piñeiro: A Journey Through Sacred Plants
- Julio Fowler: Music, Utopia, and Cannabis from Madrid
- Jurema: The Brazilian Plant Reviving the DMT Enigma
K
- K-POST will study ketamine after orthopedic trauma: trial announced
- Kanna (Sceletium tortuosum): The Mild Sedative of the San and Khoi
- Kava: The Pacific’s Sedative Root and Its Complexities
- KET 01: less dissociation, but depression primary endpoint not met
- Ketamine and abstinence: an early signal with uncertain sustained benefit
- Ketamine and AMPA receptors: PET correlations in depression
- Ketamine and depression: KARMA-Dep 2 finds no superiority
- Ketamine and esketamine: liver findings in a small cohort
- Ketamine and fibromyalgia: uncontrolled two-year observations
- Ketamine and MDMA: methylation changes in peripheral samples
- Ketamine and MDMA: peripheral methylation in two distinct cohorts
- Ketamine and morning cortisol: an inconclusive link with suicidal ideation
- Ketamine and OCD: a 15-study review and evidence limits
- Ketamine and pain: distinct correlates, not proven independent pathways
- Ketamine and psychotherapy for neuropathic pain: a feasibility pilot
- Ketamine and smoking reduction: an open pilot in seven people
- Ketamine and spatial memory: a mechanistic study in 40 adults
- Ketamine and the habenula: aversive responses in 70 healthy adults
- Ketamine and Treatment-Resistant Depression: What the Clinical Evidence Shows
- Ketamine During C-Sections and Postpartum Depressive Symptoms: Meta-Analysis
- Ketamine in bipolar depression: a two-week trial signal
- Ketamine in cancer surgery: no association with lower mortality
- Ketamine in psychiatry: narrative synthesis of evidence and risks
- Ketamine Risks: Cystitis, Dependence, and the K-Hole
- Ketamine versus lidocaine: a refractory cancer-pain trial
- Ketamine-related urinary harm: 60 young patients at Alder Hey
- Ketamine: Between Anesthesia and Neuronal Regeneration
- Khat: The Plant With an Amphetamine in Its Leaves
L
- Legal Biases in Drug Research: Between Fear and Science
- Legal Psychoactive Plants: The Other Side of Prohibition
- Leonardo da Vinci and Hemp: War, Cuisine, and Myth
- Levo-Alpha Acetylmethadol: History of a Forgotten Opioid
- Lilly and AtaiBeckley: completed deal, contingent value separate
- Lilly announces an AtaiBeckley acquisition agreement with contingent payments
- Literary Roots of Psychedelia: From Osmond to Kerouac
- Long-Term Effects of Ritual Ayahuasca Use: Science and Harm Reduction
- Louisiana establishes a framework for psychedelic research
- Low-dose LSD for ADHD: review finds no demonstrated superiority
- Low-dose psilocybin: a phase 1 trial in 56 healthy adults
- LSD analogs in rats: metabolic conversion and the LSZ exception
- LSD and anxiety: preliminary Panorama results from Definium
- LSD and anxiety: preliminary Voyage results from the sponsor
- LSD and brain rhythms: a 17-volunteer MEG reanalysis
- LSD and Generalized Anxiety: What the Phase 2b Trial Revealed
- LSD and motor learning: next-day improvement after rest
- LSD and mouse gene expression: an adaptive-stress hypothesis
- LSD and Music: Science, Perception, and Harm Reduction
- LSD and Suggestibility: Between Therapy, Risk, and the Mind
- LSD Applications in Psychotherapy: An Interrupted History
- LSD at the End of Life: What the Peter Gasser Trial Revealed
- LSD in Humans: PET-MRI Shows 5-HT2A Occupancy and Increased Brain Blood Flow
- LSD Microdoses: Subjective Visual Changes but No Effect on a Contrast Illusion
- LSD microdosing and attention in women: a pilot finding
- LSD Psychotherapy: A History Interrupted
- LSD Temporary Tattoos: Anatomy of an Urban Legend
- LSD Therapy: Why Research Actually Stalled
- LSD, psilocybin and 2C-B: rat metabolic patterns compared
- LSD: Acute Effects, Pharmacological Profile, and Harm Reduction
- LSD: My Problem Child (Preface)
M
- Mandrake, Lotus, and Lettuce: Psychoactives in Pharaonic Egypt
- Mapping the Ineffable: The Science of Measuring Subjective Effects
- Mapping the Invisible: Science and Subjectivity in Drug Effects
- MAPS comments on a reported MDMA application resubmission
- Market Analysis: How Much Does LSD Cost on the Dark Web?
- Market Volatility: MDMA Purity and Adulteration in Spain
- Master Plants and Their Disciples
- Master Plants and Their Disciples
- MDMA and alcohol intake: an experiment in msP rats
- MDMA and cocaine in Luxembourg wastewater: 2024 patterns
- MDMA and couples therapy for PTSD: an eight-couple pilot
- MDMA and military PTSD: funding and two research designs
- MDMA and Pain Relief: Science, Risk, and Perspective
- MDMA and psychedelics: self-attributed health outcomes in a survey
- MDMA and PTSD in veterans: potential contraindications in records
- MDMA and PTSD: seven-trial meta-analysis and its limitations
- MDMA and PTSD: What Phase 3 Trials Say About Efficacy
- MDMA and Social Bonding: Selective Empathy, Generosity, and Context
- MDMA childhood-trauma pilot: fifteen planned participants
- MDMA comedown: what a survey of 497 people found
- MDMA for PTSD: MAPS responds to a reported new submission
- MDMA for veterans with PTSD and alcohol use: VA trial
- MDMA, Empathy, and Compassion: Does It Transform Social Behavior?
- MDMA, Fear, and Empathy: What Affective Neuroscience Reveals
- MDMA-Assisted Psychotherapy and Autism Spectrum Disorder
- MDMA-Assisted Psychotherapy: From Merck Patent to PTSD Treatment
- MDMA-assisted therapy and PTSD: a low-certainty living review
- Mebeverine and false-positive MDMA screens: three cases and a check
- Medical cannabis and Schedule III: a September US stay order
- Medicine, Poison, and Molecules: What Canary Broom Really Contains
- Meditation and Cannabis: The Brain’s Perspective on Stillness
- Mescaline and DEA: Teesto chapter seeks exclusion from an application
- Mescaline in awake rats: cerebellar BOLD signal and connectivity
- Mescaline in rats: BOLD signal and sensory gating with limits
- Methadone for Opioid Addiction: History, Efficacy, and Harm Reduction
- Methylone TSND-201 and PTSD: phase 2 findings and safety limits
- Methylphenidate and ADHD: Formulations and Diagnostic Doubts
- Methylphenidate: The ADHD Pill Between Clinic and Abuse
- Miami retreat death: charges and limits of verified information
- Microdosing and cognition: high-overlap review without demonstrated enhancement
- Microdosing and psychological symptoms: randomized evidence remains inconclusive
- Microdosing: reports from 5,399 survey participants
- Miguel Ángel Velasco: Poetry and Visionary Trance
- Mind vs. Soul: An Introspective Poem
- Modern Rituals and Collective Consciousness: Beyond Psychedelic Dogma
- Mountain Risks vs. MDMA: A Data-Driven Medical Comparison
- MSICS reports funding and psilocybin plans in Israel
- Multiple Sclerosis and Cannabinoids: An Evidence-Based Approach
- Multiple Sclerosis and Cannabinoids: Evidence-Based Symptom Relief
- Mulungu: The Amazonian Tree With Calming Effects
- Mummies as Drugs: Anatomy of a Psychonautic Hoax
- Mushroom Season: A Culinary Guide to Fungi and Cannabis
N
- Naloxone and Opioid Overdose: Between Clinical Evidence and Social Barriers
- Naltrexone: Mechanisms, Risks, and Realities in Addiction Treatment
- Natem: Shuar Ayahuasca and a Ritual Filmed in Shaime
- Nausea During Pregnancy: Cannabis, Myths, and Safe Alternatives
- NEP in samples sold as “mephes”: Energy Control warning
- New Mexico: reported applications for psilocybin producers
- New South Wales announces continued festival drug checking
- New Zealand: two individual approvals to prescribe MDMA
- Nexus 2026: Consciousness, Art, and Cognitive Liberty
- NHS psilocybin: a feasibility trial with inert placebo
- NIDA funds ibogaine research: planned phases and limitations
- Nitrous Oxide and Driving: Gas Confirmed in Blood in 34 of 44 German Cases
- Noribogaine DMX-1001: research clearance, not marketing approval
- NSW Health Warns of High-Dose MDMA Tablets Detected at a Sydney Festival
O
- On the Icaro, or Shamanic Chant
- Online ketamine: what the FDA warning to LyfeUnit establishes
- Opium and Coffee: The History of Smart Drugs in Europe
- Opium in Ancient Egypt: Medicine, Ritual, and Trade
- Opium in Ancient Rome: Everyday Medicine of an Empire
- Oral KET01: less dissociation, primary efficacy unproven
- Oral psilocin and psilocybin: comparison in 20 healthy adults
- Oral vs. Inhaled Cannabis for Multiple Sclerosis: Balancing Safety
- Oregon psilocybin centers: phone screening and $1,900 sessions
- Oregon psilocybin services: reported changes in an observational cohort
- Oregon withdraws proposed psilocybin fee increases
- Oregon: OHA dropped the proposed fee increases
- Orphines and test strips: a negative result does not rule them out
- Orthostatic Hypotension and Cannabis: Science, Prevention, and Safety
P
- Palomiscina: Anatomy of an Internet Drug Hoax
- Papaver somniferum: History and Culture of the Opium Poppy
- PATH Caucus proposals on access to psychedelic therapy
- Peganum harmala: The European Ayahuasca Examined
- Peyote (Lophophora williamsii): The Mescaline Cactus
- Phantom Limb Pain and Cannabinoids: An Evidence-Based Approach
- Pharmaceutical LSD: Emerge reports a phase 3 depression signal
- Pharmacophilia and Idiosyncrasy: Jonathan Ott’s Talk
- Piracetam: The Origin of Smart Drugs
- PIVOT: psilocybin trial in veterans with an active comparator
- Plant tryptamines: a synthetic-biology proof of concept
- Plants That Promise a High and Deliver Nothing: Debunking Myths
- Plants, Shamanism, and States of Consciousness
- PLASTICITY: Berkeley’s psilocybin and aging study design
- Pleasure and Risk: A New Approach to Drug Education
- Porn Addiction: Superstimulus or Neurological Myth?
- PP and PSOE on Cannabis: Two Ways to Say No
- Products sold as CBD: what a report says about undeclared cannabinoids
- Project Ideaa: Integrative Therapy for Addiction Treatment
- PsiDeR: psilocybin versus placebo in a feasibility trial
- Psilocybin after repeated impacts: a female-rat study
- Psilocybin and alcohol: six trials with evidence still mixed
- Psilocybin and Alcoholism: What the JAMA Randomized Trial Shows
- Psilocybin and Anorexia Nervosa: The First Feasibility Study
- Psilocybin and anorexia: an uncontrolled 21-woman pilot
- Psilocybin and apomorphine in coma: an early-trial protocol
- Psilocybin and bipolar II depression: a 14-person open pilot
- Psilocybin and Cancer: Single Dose Shows Two-Year Benefits
- Psilocybin and chemotherapy nerve injury: preclinical findings
- Psilocybin and context: brain patterns in 62 healthy volunteers
- Psilocybin and dementia: one observed case, without proven efficacy
- Psilocybin and Depression: Breaking the Rumination Loop
- Psilocybin and Depression: Neuroimaging, Regulation, and the Search for a New Therapy
- Psilocybin and depression: use was not linked to less treatment in a US survey
- Psilocybin and Major Depression: What Recent Clinical Trials Say
- Psilocybin and methamphetamine: associations in brain networks
- Psilocybin and migraine: no significant primary pilot difference
- Psilocybin and neuronal bursts: recordings from 35 mice
- Psilocybin and OCD: mystical-experience association in 27 people
- Psilocybin and OCD: open-label waitlist preprint with 37 people
- Psilocybin and phantom-limb pain: a nine-person pilot
- Psilocybin and post-Lyme symptoms: a 20-patient open-label pilot
- Psilocybin and PTSD in veterans: signals from an open pilot
- Psilocybin and rat grooming: a clue about 5-HT2B receptors
- Psilocybin and the brain: one-month diffusion changes, acute entropy
- Psilocybin and the SV2A marker: a nonsignificant primary result
- Psilocybin and Treatment-Resistant Depression: What the EPISODE Trial Shows
- Psilocybin for anorexia: preliminary signals in a pilot without a control group
- Psilocybin for Bipolar II Depression: JAMA Psychiatry Trial Results
- Psilocybin in mice: 5-HT2A and synaptic remodeling
- Psilocybin in mice: sociability after administration under anaesthesia
- Psilocybin in palliative care: a signal in an open pilot
- Psilocybin: Emotional and Cognitive Modulation Under Scientific Lens
- Psychedelic decriminalization: perceptions in a 163-person survey
- Psychedelic Integration: From the Trip to Lasting Change
- Psychedelic Medicine: A Practical Guide for Patients and Clinicians
- Psychedelic Microdosing: What Placebo-Controlled Trials Reveal
- Psychedelic neuroimaging: shared patterns with uncertainty
- Psychedelic Psychotherapy Examined: What Does Evidence Say?
- Psychedelic Visions and the Brain: Beyond Huxley
- Psychedelics: A Brief Introduction
- Psychoactive Stimulant Plants: A Comprehensive Guide
- Psychonauts on the Net
- Puerto Rico orders evaluation of a potential emerging-therapies pilot
Q
R
- Real Efficacy of Cannabis Oil Rubs: Science, Myths, and Harm Reduction
- Reality Tunnels and Imprints: The Eight-Circuit Model
- Recreational vs. Clinical Ketamine: Uses and Harm Reduction
- Regulated psilocybin in Oregon: three-month observational outcomes
- Regulated psilocybin: a preprint observes changes and safety signals
- Regulating Drugs (Part 5): Demand, Home Cultivation, and Prevention
- Regulating Drugs: Sales, Legal Age, and Pricing Models
- Relaxation and Cannabis: Mechanisms, Techniques, and Cautions
- Religious psilocybin in Utah: what the Tenth Circuit decided
- Rimonabant: The Drug That Blocked the Mind Before the Appetite
S
- Sacred or Frivolous? The Myth of the Strictly Ritual Psychedelic
- Sacred Plants and Ethnomedicine: From Kava to Iboga
- Sagunto and Ayahuasca: Cognitive Liberty Needs Clear Rules
- Salvia divinorum Effects: Why They Are So Intense and Brief
- Salvia divinorum: Legal Status in Spain and Worldwide
- Salvia divinorum: Real Risks and Harm Reduction Essentials
- Salvia divinorum: The Visionary Plant of the Mazatecs
- Salvinorin A in humans: a 12-trial review and its limitations
- Salvinorin A: The Most Potent Natural Psychedelic and the Kappa Receptor
- San Pedro (Trichocereus): Mescaline from Andean Cacti
- San Pedro: The Andean Mescaline Cactus
- Santa Claus and the Shamanic Origins of Amanita muscaria
- Santa Claus and the Shamanic Origins of Christmas
- Shamanic Journeying Without Hallucinogens
- Shulgin (I): The Chemical Vocation of a Psychonaut
- Shulgin (II): Mescaline, the DOM Case, and the Solo Path
- Shulgin and MDMA: From Merck’s Archives to the Personal Lab
- Shulgin and MDMA: From the Merck Archives to the Home Lab
- Shulgin and the LSD Flashback Myth: What Pharmacology Says
- Shulgin vs. the War on Drugs: Civil Liberties at Stake
- Simplified LSD analogues: preclinical signals, not medicines
- Sisa or “Poor Man’s Drug”: Anatomy of a Media Panic
- Ska-P and “Cannabis”: Protest Music Against Prohibition
- Snow Sports and MDMA: A Rigorous Look at Vital Risks
- Sobria Ebrietas: Escohotado on the History of Intoxication
- Spanish Fly: Between Historical Legend and Chemical Reality
- Speed: History and Myths of Street Amphetamine
- Spiderwebs and Hallucinations: Urban Myth vs. Scientific Reality
- Stiff-Person Syndrome: Neurophysiology and Therapeutic Cannabis
- Subcutaneous and Intravenous Esketamine in Treatment-Resistant Depression: Retrospective Study of 72 Patients
- Suffering Is Not a Malfunction: Rethinking Human Distress (I)
- Suicidal Ideation Modestly Lower After Four Ketamine Infusions in Open-Label Trial
- Sulbutiamine: The Vitamin B1 Derivative Known as a Nootropic
- Sulbutiamine: What the Evidence Says About This Mild Stimulant
- Sustainable Drugophilia: Regulating Drugs Instead of Prohibition
- Sustainable Hedonism (Part 7): Safer Drugs and Destigmatizing Users
- Sustainable Hedonism: From Prohibition to Pleasure Management
- Sydney drug checking: unexpected contents in 16 of 77 samples
- Synthetic Cannabinoids: A Safe Substitute for Medical Cannabis?
- Synthetic Cannabinoids: Between Technical Legality and Vital Risk
- Synthetic Cannabinoids: The Shadow of Modern Recreation
- Synthetic Cannabinoids: The Spice Phenomenon and Hidden Risks
T
- Tampodka: Anatomy of a Summer Drug Hoax
- Teesto asks DEA to deny Benuvia’s mescaline application
- Testosterone: Between Biology, Power, and the Construction of Gender
- Texas and ibogaine: IMPACT funding and limits of the reported launch
- The 1965 Paper That Turned a Canary Broom Into a “Minor Psychedelic”
- The 2008 Ban on Psilocybin Mushrooms in the Netherlands
- The Amsterdam Hash Marihuana & Hemp Museum: Forgotten History
- The Art of Cannavaping: Science, Risks, and Therapeutic Future
- The Ayahuasca Case: A Skeptic’s Chronicle (I)
- The Bacchanalia: Ecstasy, Wine, and Rome’s First Religious Purge
- The Banana Peel Myth: Between Pop Culture and Science
- The Bwiti Ritual: Traditional Iboga Use in Gabon
- The Central Role of Entheogens in Cultural Dynamics
- The Crystal Deception: Meth Sold as Ecstasy in Spain
- The Ergot Circle: Hofmann, Ololiuqui, and LSD
- The Evolution of Drug Advertising: From Prohibition to Responsibility
- The Food of the Gods: Psilocybin and Human Evolution
- The Forgotten Entheogens of Old Mediterranean Europe
- The Foster’s Beer LSD Synthesis Legend: Myth vs. Chemical Reality
- The Green Virus: A Cannabis Dystopia About Freedom
- The Haitian Zombie Myth: Science, Faith, and Clairvius Narcisse
- The Hallucinogenic Divinities: Alain Daniélou on Entheogens
- The Historical Eclipse of Entheogens
- The History of Ketamine: From the Operating Room to Psychiatry
- The HIV Syringe in the Movie Theater Seat Hoax
- The Invisible Ally of the Monteverde: The Canary Broom’s Secret Life
- The Medicinal Side of Five Psychoactive Plants
- The Medicinal Side of Power Plants
- The Most Well-Known Chemical Psychoactives
- The Myth of the Miracle Oil: Why Rick Simpson’s Case Isn’t Science
- The Opioid Crisis: Heroin, Morphine, and the Pharmaceutical Industry
- The Plant With Three Names: The True Story of the Canary Island Broom
- The Renaissance of LSD in Clinical Research for Palliative Care
- The Rick Simpson Myth: Between Desperate Hope and Science
- The Risk of a Psychedelic Theocracy: Mysticism vs. Rigorous Science
- The Role of Physicians in Medical Cannabis: Reality and Myths
- The Science of Aspirin and Coke: Debunking a Persistent Myth
- The Shadow of the Stimulant: Methamphetamine and Europe’s New Challenges
- The Silent Awakening of the Mushroom
- The Sixth Decade of Cannabis: A Century of Silence and Science
- The Therapeutic User: Rigor, Responsibility, and Science in Clubs
- The Truth About Amphetamine Storage: Myths vs. Chemical Reality
- The Truth About Rat Poison in Drugs: History, Science, and Myths
- The Truth About Smoking Toothpaste: Myths, Fluoride, and Science
- The Truth About Therapeutic Cannabis: Hope vs. Scientific Evidence
- The Wheel of Time: Castaneda’s Teachings of Don Juan
- Therapeutic Cannabis: History, Law, and Myth
- Therapeutic Cannabis: Scientific Obstacles and the Shadow of Prohibition
- Tolerance and Loss of Effects: Pharmacological Keys to MDMA
- Toxicomania: The Substance or the Temperament?
- Traditional Mazatec Use: María Sabina and the Leaves of the Shepherdess
- Tramadol: The Atypical Opioid That Doesn’t Act Like One
- Tucara: The Musical Fusion of Andreas Lutz and Alba Molina
- Turkestan Mint: The Forgotten Sedative of Central Asia
- Turkestan Mint: The Forgotten Sedative of Central Asia
U
- Ultra-Short Tryptamines: DMT and 5-MeO-DMT in Psychedelic Medicine
- UMBRAA: a proposed placebo strategy for psychedelic trials
- Understanding Amines: Chemistry of Psychoactive Compounds
- Understanding Iboga: The African Shrub and Ibogaine Alkaloid
- Urinary Incontinence and Cannabinoids: Clinical Evidence and Risk Reduction
- Urine Drug Tests: Scientific Reality and Myths About Cannabis
- US notice on carfentanil and other fentanyl analogues
V
W
- We Are Standard: Danceable Pop, London, and the Cannabis Question
- WEDINOS detects opioids and substitutions in submitted samples
- Weed Fertilized with LSD: Anatomy of an Urban Legend
- Welcome to Psiconáutica
- Welcome Traveler to Your First Gateway
- Wet Hashish: How to Dry It and When to Throw It Away
- What Canary Broom Can Still Teach Science
- What Is Ketamine: Pharmacology, Effects, and Medical Uses
- What Is Salvia Divinorum: The Mazatec Visionary Plant
- When Crack Replaces Heroin in Madrid
- Why Marijuana Is Illegal: The History of Prohibition
- Wild Lettuce and Lactucarium: The “Opium” That Wasn’t
- Wild Psychoactive Plants of the Iberian Peninsula (Part 1)
- Wine in Classical Greece: Ritual, Law, and Phármakon
- Winnipeg opens a supervised consumption site as Calgary closes its facility
- Witchcraft and Its Plants: A History of Visionary Flora
